Company news

Lantheus Holdings, Inc. news in 2026

Lantheus Holdings, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals

November 5, 2026

Lantheus Reports Third Quarter 2026 Financial Results

November 5, 2026

Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting

November 2, 2026

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

September 30, 2026

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

September 28, 2026

Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs

September 22, 2026

Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease

August 14, 2026

Lantheus Reports Second Quarter 2026 Financial Results

August 6, 2026

Lantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8: 00 a.m. Eastern Time

July 23, 2026

Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)

June 26, 2026

Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

June 3, 2026

Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year

June 1, 2026

Lantheus to Present at the William Blair 46th Annual Growth Stock Conference

May 27, 2026

Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting

May 21, 2026

Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

May 18, 2026

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026

Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8: 00 a.m. Eastern Time

April 23, 2026

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

March 16, 2026

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

March 5, 2026

Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®

March 2, 2026

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

Lantheus to Present at March 2026 Investor Conferences

February 24, 2026

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8: 00 a.m. Eastern Time

February 12, 2026

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies

January 1, 2026

Calls in 2026

Decks in 2026